Navigation Links
World Virology and Bacteriology Testing Sector Discussed in Comprehensive VPG Research Report Published at MarketPublishers.com
Date:7/11/2014

London, UK (PRWEB) July 11, 2014

Microbiology testing is a highly dynamic and rapidly growing segment of the in-vitro diagnostics industry, which is expected to pose the biggest challenge to suppliers in the next ten years. The sector owes its growth to the ongoing spread of AIDS – still the key threat to people’s health worldwide and a major factor leading to the upsurge of opportunistic infections, novel molecular diagnostic technologies, threat of bio-terrorism, and a broader availability of immunosuppressants, among others.

Market maturity, fierce competition, cost containment solutions, technological edge and limitations, patent rights protection, regulatory restrictions, and decentralised testing market challenges, among others, fall within the major factors limiting the sector’s growth.

Comprehensive research report “Emerging Opportunities in the Global Virology and Bacteriology Testing Market” worked out by Venture Planning Group (VPG) is now available at MarketPublishers.com.

Report Details:

Title: Emerging Opportunities in the Global Virology and Bacteriology Testing Market
Published: June, 2014
Pages: 1900
Price: US$ 32,500.00

Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld
2. Worldwide Chic Ladies Can Buy Cheap Evening Dresses at iFitDress.com
3. Organic Crop Farming in Australia Industry Market Research Report Now Available from IBISWorld
4. Woodland Hills Dental Expert Speaking at Nobel Biocare World Symposium in One Week
5. As World Cup Comes to an End, Injuries are Star of the Show
6. World interest in research work on the benefits of the Okra plant
7. DARPA selects Lawrence Livermore to develop worlds first neural device to restore memory
8. Cancer Research UKs new funding scheme to nurture future world-leading scientists
9. Blind lead the way in brave new world of tactile technology
10. 2014 World Stem Cell Summit presented by GPI, Mary Ann Liebert, Inc, and GEN
11. Quest for education creating graying ghost towns at top of the world
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... September yoga month was created by ... and its health benefits. To support this Ekhart Yoga ... "Yoga Month Challenge" , This 4 week guided online ... experienced yogis practice yoga regularly from their own home. ... ' is suitable for all levels, and the dynamic ...
(Date:8/29/2014)... 29, 2014 RBS Reputation Management has brought ... The service is to help those individuals and organizations ... on Scam Book. The service would push down the ranking ... Book complaints fully invisible on Google. , RBS Reputation ... On being asked how company can provide guarantee of results ...
(Date:8/29/2014)... week, the Fed reported an increase in industrial ... to 0.4% while manufacturing output progressed to 1.0%. , ... since February this year. Capacity use has increased by more ... an increase that could be attributed to the boost in ... is a measure of slack across the industries. , Output ...
(Date:8/29/2014)... 2014 Ethane Web Technologies, an ISO ... new service named HTML web design. , The HTML ... tailoring the service, Ethane Web Technologies did extensive research ... company has done its best efforts to make sure ... deliver outstanding results to clients. The company uses ...
(Date:8/29/2014)... well-studied neuroregenerative effect, stimulating neurite extension in ... vitro, and enhancing nerve regeneration following nerve ... of FK506 to stimulate nerve regeneration is ... failure and hypertension, and its considerable cost. ... with other drugs reportedly cause life-threatening infections. ...
Breaking Medicine News(10 mins):Health News:Ekhart Yoga Launches the Yoga Month Challenge 2Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 2Health News:LeaseQ Announces That Recent Industrial Production Report Spells Good Things For The Equipment Leasing Industry 3Health News:Ethane Web Technologies Launches a New Web Design Service 2
... you were at high risk of cancer because you carry ... A recent study at Fox Chase Cancer Center not only ... level and studied the parent perceptions of the impact of ... at the 2009 Annual Meeting of the American Society of ...
... study of targeted educational initiatives between the clinical staff ... their Partners program suggest that educational interventions by academic ... patients at community hospitals. The study, to be ... Society of Clinical Oncology, looked specifically at the number ...
... 14, 2009)Researchers at Fox Chase Cancer Center uncovered a ... tumor (GIST) patients respond to the targeted therapy imatinib ... that could be suppressed in order to make these ... PhD, a postdoctoral fellow in the laboratory of Andrew ...
... guide important treatment decisions, experts say , , THURSDAY, May ... at predicting colon cancer recurrence may help individualize treatment ... therapy choices, scientists say. , The Oncotype DX test ... more likely to have a recurrence and which were ...
... of new pharmaceutical products in the pipeline combined with ... for the rare disease community, a senior Food and ... hosted by the National Organization for Rare Disorders (NORD).The ... MD, director of the Center for Drug Evaluation and ...
... proteomic test as a predictor of overall survival benefit ... VeriStrat, a blood-based, proteomic test currently used for patients ... presented by Christine Chung, MD, Assistant Professor of Medicine ... at the 45th Annual Meeting of the American Society ...
Cached Medicine News:Health News:Should parents share the results of BRCA1/2 genetic testing with their children? 2Health News:Educational initiatives improve quality of care delivery 2Health News:Gene signature may predict patient response to therapy for gastrointestinal stromal tumors 2Health News:Gene Screen May Predict Colon Cancer's Return 2Health News:Gene Screen May Predict Colon Cancer's Return 3Health News:NORD Sponsors Rare Disease Summit 2Health News:May 14, 2009: Biodesix Announces VeriStrat(R) Data in Head and Neck Cancer to be Presented at ASCO 2Health News:May 14, 2009: Biodesix Announces VeriStrat(R) Data in Head and Neck Cancer to be Presented at ASCO 3
(Date:8/28/2014)... Takeda Pharmaceutical Company Limited ("Takeda") today announced ... of data from a 10-year epidemiology study to ... (U.S.) Food and Drug Administration (FDA), ... Ministry of Health, Labour, and Welfare (MHLW) / ... for pioglitazone containing medicines, including ACTOS (pioglitazone HCl). ...
(Date:8/28/2014)... , Aug. 28, 2014  In anticipation of the upcoming ... being made available for the first time. Industry Overview: ... offers a snapshot of San Diego,s ... Highlighting everything from the latest employment statistics to current venture ... San Diego such a vital part of ...
(Date:8/28/2014)... /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training firm ... a case study highlighting one manager,s experience ... In September and October 2014, Academy Leadership affiliates are ... , Indianapolis , Salt Lake City , ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for managers ...
Breaking Medicine Technology:Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 2Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 3Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 4Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 5Takeda Announces Completion of the Post-Marketing Commitment to Submit Data to the FDA, the EMA and the PMDA for Pioglitazone Containing Medicines Including ACTOS 6New Infographic Published - Overview of Medtech & Life Sciences Industry in San Diego 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... , FRIMLEY, England, December 8 ... Measures of Treatment Effectiveness,in the Trial, in Patients With Newly-Diagnosed Disease(1) , ... Later Stages,of the Disease on nilotinib (300mg Twice-Daily and 400mg Twice-Daily) Than ... Well Tolerated; Only a Small Number of Patients,Discontinued Due to Adverse Events(1) ...
... Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical ... cancer, inflammation and autoimmune diseases, today announced data from ... patients with B-precursor acute lymphoblastic leukemia (ALL). The data ... Annual Meeting of the American Society of Hematology (ASH) ...
Cached Medicine Technology:Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4
P-Series Cystourethroscope Short Bridge, examining...
Short double-horn bridge for insertion of instruments...
Designed for accurate articulation of flexible devices....
... Used for stone manipulation and removal in the ... basket to retain its shape following extreme torsion. ... capture by allowing the basket to open at ... stone. The tipless design reduces the likelihood of ...
Medicine Products: